Genentech

News

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.

News

Roche looks to Astex in $515m breast cancer deal

Roche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.

News

FDA approves first generic of Roche's flu drug Xofluza

The first generic of Roche's drug for influenza, Xofluza, has been approved by the FDA and should be available in time for this year's flu season.

News

GSK reaches $2.2bn deal to buy food allergy biotech RAPT

GSK has made its first major acquisition under new CEO Luke Miels, buying RAPT Therapeutics and its food allergy prevention drug ozureprubart.

News

Nine more companies sign pricing deals with Trump

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Roche looks to Astex in $515m breast cancer deal

FDA approves first generic of Roche's flu drug Xofluza

GSK reaches $2.2bn deal to buy food allergy biotech RAPT

Nine more companies sign pricing deals with Trump

As year-end nears, pharma groups plump up their pipelines

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Genentech

Editor's Picks